Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
European Journal of Clinical Pharmacology • 2005 | View Paper
“A greater than 80% reduction of total ventricular ectopic depolarizations was obtained in eight of nine patients given flecainide and in five of ten patients given quinidine (p = 0.09).”
“The uptake of flecainide into intestinal epithelial LS180 cells was decreased significantly by acidification of the extracellular medium, and was inhibited by tertiary amines, such as diphenhydramine and quinidine.”
Biopharmaceutics & drug disposition • 2014 | View Paper
“Uptake transporter substrate assay revealed that flecainide (1 µM) showed 1.11-fold accumulation though the hMATE1-related active transport was significantly decreased in the presence of quinidine (42.0 ± 23.9 vs. 11.8 ± 4.1 pmol/mg in transfected cells; p < 0.05).”
Biological & pharmaceutical bulletin • 2019 | View Paper
“Although propafenone had little effect on the rate of ITO recovery from inactivation (tau CONTROL = 64 +/- 5 ms; tau PROPAFENONE = 84 +/- 9 ms), ITO recovery in the presence of flecainide and quinidine was biexponential; it exhibited an additional slow component (tau FAST = 67 +/- 5 ms and tau SLOW = 2580 +/-”
“Although propafenone had little effect on the rate of ITO recovery … PROPAFENONE = 84 +/- 9 ms), ITO recovery in the presence of flecainide … quinidine was biexponential; it exhibited an additional slow component (tau FAST = 67 +/- 5 ms …; tau FAST = 55 +/- 5 ms and tau SLOW = 871 +/- 99 ms for quinidine).”
The Journal of pharmacology and experimental therapeutics • 1994 | View Paper
“The greatest contributing factor for quinidine was an increased effective refractory period/APD ratio, for lidocaine a slower restitution and for flecainide and mexiletine the shift of the restitution curve.”